HC Wainwright Reaffirms "Buy" Rating for Oruka Therapeutics (NASDAQ:ORKA)

Key Points

• HC Wainwright reaffirmed a “Buy” rating on Oruka Therapeutics with a $120 price target, implying 33.44% upside from the prior close. The stock has a “Moderate Buy” consensus rating and an average analyst target of $133.
• Oruka shares opened at $89.93 after falling 4.9%; the company also reported quarterly EPS of -$0.55, missing the consensus estimate of -$0.51.
• Phase 2a data for ORKA-001 showed deepening psoriasis responses through Week 28, including 71.4% PASI 100 and 87.3% PASI 90 response rates, though investors still await later-stage data and the stock declined despite the update.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report)'s stock had its "buy" rating reissued by equities research analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They currently have a $120.00 price target on the stock. HC Wainwright's price target would indicate a potential upside of 33.44% from the stock's previous close.

ORKA has been the topic of a number of other reports. Piper Sandler reissued an "overweight" rating and set a $180.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Wedbush reaffirmed an "outperform" rating and issued a $165.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. BTIG Research reaffirmed a "buy" rating and issued a $151.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Mizuho set a $120.00 price objective on Oruka Therapeutics in a research report on Thursday, September 3rd. Finally, Guggenheim reissued a "buy" rating and set a $200.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $133.00.

Oruka Therapeutics Trading Down 4.9%

Shares of NASDAQ ORKA opened at $89.93 on Thursday. Oruka Therapeutics has a 1 year low of $14.89 and a 1 year high of $115.51. The firm's 50-day moving average is $96.79 and its 200-day moving average is $75.32. The firm has a market capitalization of $5.95 billion, a PE ratio of -44.30 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.04). As a group, equities research analysts anticipate that Oruka Therapeutics will post -2.42 earnings per share for the current fiscal year.

Insider Transactions at Oruka Therapeutics

In related news, SVP Arjun Agarwal sold 533 shares of the firm's stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $95.75, for a total transaction of $51,034.75. Following the transaction, the senior vice president directly owned 14,219 shares of the company's stock, valued at approximately $1,361,469.25. This trade represents a 3.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of the business's stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $92.38, for a total transaction of $734,143.86. Following the completion of the sale, the insider directly owned 31,771 shares of the company's stock, valued at $2,935,004.98. This represents a 20.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 122,950 shares of company stock valued at $11,528,806. 23.49% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Nykredit A S bought a new stake in shares of Oruka Therapeutics in the 2nd quarter worth approximately $29,000. Orion Capital Management LLC bought a new position in shares of Oruka Therapeutics during the 2nd quarter worth $91,000. Natural Investments LLC purchased a new stake in Oruka Therapeutics in the 2nd quarter worth about $202,000. Caitong International Asset Management Co. Ltd bought a new stake in Oruka Therapeutics in the 4th quarter valued at about $67,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Oruka Therapeutics during the second quarter valued at about $211,000. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

Key Oruka Therapeutics News

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: ORKA-001 produced deepening psoriasis responses without additional dosing after Week 4. By Week 28, the PASI 100 response rate reached 71.4% and the PASI 90 rate reached 87.3%, supporting the potential for durable disease control from the half-life-extended IL-23p19 antibody. Oruka Therapeutics Week 28 Data Announcement
• Positive Sentiment: Patients who crossed over from placebo also achieved PASI 90 and PASI 100 response rates comparable to those initially treated with ORKA-001, while the therapy maintained a favorable safety and tolerability profile through Week 28. EVERLAST-A Week 28 Results
• Neutral Sentiment: The results remain from a mid-stage Phase 2a study, so investors still need larger and later-stage data to assess efficacy, durability, safety, and the drug’s competitiveness against established psoriasis treatments. The company expects full 52-week EVERLAST-A data in December 2026 and EVERLAST-B Week 16 data in the fourth quarter of 2026. What the Phase 2a Data Means for Shareholders
• Negative Sentiment: Despite the improving response rates, ORKA shares fell as investors appeared to treat the update as insufficient for further upside, potentially reflecting profit-taking and high expectations already embedded in the stock. Reports specifically highlighted that the shares declined despite the deepening responses. Oruka Shares Fall Despite Deepening Week 28 Responses

About Oruka Therapeutics

Oruka Therapeutics, Inc NASDAQ: ORKA is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company's research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka's initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.